Read about the latest advances from the Lady Davis Institute for Medical Research (LDI) and its researchers, including new findings, grant awards, innovations, and collaborations.
New study links GLP-1 receptor agonists to increased risk of gastroesophageal reflux disease (GERD) in type 2 diabetes patients
The study shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which include Ozempic®, Rybelsus® and other widely- prescribed drugs for type 2 diabetes and obesity management, may increase the risk of developing gastroesophageal reflux disease (GERD) and its complications compared to sodium–glucose cotransporter-2 (SGLT-2) inhibitors (such as Brenzavvy™, Invokana®, etc.).
New study reveals promising strategy to retrain neutrophils to target breast cancer
Innovative strategy has the potential to revolutionize the treatment of breast cancer, particularly for patients who have developed resistance to targeted therapies.
Lady Davis Institute researchers and research trainees distinguish themselves in the Fonds de recherche du Québec (FRQ) 2025-2026 competitions
Nine researchers, one postdoctoral fellow, 17 PhD students and three master’s students from the Lady Davis Institute for Medical Research (LDI) are the recipients of FRQ salary and research awards within the framework of the 2025-2026 competitions.
